Pharmaceutical patenting and the transformation of American medical ethics

Dados Bibliográficos

ID8395667
AutoresJoseph M Gabriel (0000-0002-2770-3051, Florida State University, autor correspondente)
Ano2016
Volume49
Fascículo4
Páginas577-600
Data de publicação2016-12-01
Peer ReviewedSim
Open AccessSim
TipoARTICLE
PeriódicoThe British Journal for the History of Science (JOURNAL)
Identificadores do periódicoISSN: 0007-0874 • E-ISSN: 1474-001X
EditoraCambridge University Press (CUP) (PUBLISHER)
DOI10.1017/s0007087416001138
PMID27881189
OpenAlexW2551196832
IdiomaEN
Citações recebidas3
Referências citadas55

The attitudes of physicians and drug manufacturers in the US toward patenting pharmaceuticals changed dramatically from the mid-nineteenth century to the mid-twentieth. Formerly, physicians and reputable manufacturers argued that pharmaceutical patents prioritized profit over the advancement of medical science. Reputable manufactures refused to patent their goods and most physicians shunned patented products. However, moving into the early twentieth century, physicians and drug manufacturers grew increasingly comfortable with the idea of pharmaceutical patents. In 1912, for example, the American Medical Association dropped the prohibition on physicians holding medical patents. Shifts in wider patenting cultures therefore transformed the ethical sensibilities of physicians

Business · Drug industry · Economics · Engineering ethics · Medical ethics · Pharmaceutical industry · Political science · Profit (economics · Biomedical Ethics and Regulation · Engineering · Historical Medical Research and Treatments · Law · Medicine · Pharmaceutical industry and healthcare · Pharmacology